Amylyx Pharmaceuticals Inc (AMLX) Q2 2026 Earnings Report

The call conveyed clear momentum: a pivotal Phase III (LUCIDITY) nearing top-line readout, active NDA and launch preparations, formal disease recognition via ICD-10 coding, a defined prevalent patient population (~160,000 U.S. patients with ~75% RYGB), and continued pipeline progress (AMX0035, AMX0114, AMX0318). Financially, the company has a solid cash balance with runway into 2028 but experienced a quarter-over-quarter cash decline (~10.4%), rising operating/SG&A costs (SG&A +40.4% YoY), and an unspecified one-time legal charge. Key risks remain: the outcome of the blinded Phase III readout and potential label limitations, early-stage EAP activation constraints, and possible additional manufacturing obligations. Overall the positives (imminent pivotal readout, launch preparedness, market opportunity, and pipeline advancement) outweigh the operational and financial headwinds discussed.

The company reiterated that LUCIDITY’s pivotal Phase III database is not yet locked but that last patient visits occurred in mid–late July with a top-line readout expected in late August or early September; the trial’s FDA‑agreed primary endpoint is reduction in the composite of Level 2 and Level 3 hypoglycemic events through week 16 and the study was conservatively powered (≥90% to detect a 35% treatment effect assuming up to a 50% placebo rate). Financially, Amylyx finished Q2 with $250.8 million in cash and marketable securities (down from $279.8M at Q1 end) and expects runway into 2028 to fund milestones including the LUCIDITY readout, potential FDA approval and a possible commercial launch in 2027; Q2 operating expenses were $45.7M (up 7% YoY) comprising R&D of $23.8M (vs $27.2M in Q2 2025), SG&A of $21.9M (vs $15.6M), and non‑cash stock‑based comp of $8.3M (vs $7.4M). Other program and operational metrics noted: prevalent U.S. PBH population ~160,000 (≈120,000 RYGB), CMO payment commitments of ~$35M through 2028, AMX0318 IND‑enabling work targeting a 2027 IND, an Early Access Program open to LUCIDITY completers and prior trial participants, an ICD‑10 code for PBH effective October 1, 2026, and that the company will enter a quiet period following database lock.